Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion.
about
Gangliosides for the treatment of diabetic peripheral neuropathyStandards of medical care in diabetes--2012Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinicMesenchymal Stem Cells as a Prospective Therapy for the Diabetic FootType 1 diabetes through the life span: a position statement of the American Diabetes AssociationMitochondrial hormesis and diabetic complicationsStandards of medical care in diabetes--2013Urogenital Autonomic Dysfunction in Diabetes.Therapeutic management of diabetic kidney disease.Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohortStandards of medical care in diabetes--2010.Diabetic neuropathy: mechanisms to managementMolecular mechanisms of diabetic vascular complicationsDiabetes regulates mitochondrial biogenesis and fission in mouse neurons.Advances in the diagnosis and management of diabetic distal symmetric polyneuropathy.Diabetes education: the experiences of young adults with type 1 diabetesEffect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) StudyDiabetes: glycaemic control in type 1Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes.Puerarin prevents high glucose-induced apoptosis of Schwann cells by inhibiting oxidative stress.Standards of medical care in diabetes--2011.The pancreas in human type 1 diabetes.Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?Mechanisms of disease: the oxidative stress theory of diabetic neuropathyDiabetic neuropathy: new strategies for treatment.Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes.Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes.Community screening for pre-diabetes and diabetes using HbA1c levels in high-risk African Americans and Latinos.Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDICPrevention and early detection of vascular complications of diabetesAutonomic nervous system function in type 2 diabetes using conventional clinical autonomic tests, heart rate and blood pressure variability measuresNerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes.Selection of aptamers specific for glycated hemoglobin and total hemoglobin using on-chip SELEX.Pharmacological treatment of diabetic peripheral neuropathy.Early diabetic neuropathy: triggers and mechanisms.Delayed Gastric Emptying Is Associated With Early and Long-term Hyperglycemia in Type 1 Diabetes Mellitus.Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.Multisystemic therapy compared to telephone support for youth with poorly controlled diabetes: findings from a randomized controlled trialA Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) With Diabetic Neuropathic PainCoenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model
P2860
Q24198249-1118509B-41B5-429F-AF9F-C918AF4999C3Q24632533-4FDBF7B3-3566-479A-946D-57215D09AC93Q26739745-E5034319-EACC-40C0-9DE9-CA861CA76A21Q28074810-6C44091C-785E-4055-91F1-674D3B839575Q28242092-298816CA-B71B-46E4-82C4-6EAC3DFED818Q28388387-8712F46A-EA19-4311-A94B-BFC5B46E8F05Q29620309-C7929766-39C3-4DDF-B40E-D9E472FC8F0BQ30244250-071D3318-9438-499D-A4A2-771E2F2B20BFQ30362729-CDA99422-D865-4C8E-9617-0C705E0712C8Q30436948-D63E4E1D-868A-4664-9A71-43AF30BF5083Q33554238-C63A21A2-77AA-4987-BE45-155D57252DE9Q33554384-8316F5D0-08FC-4D56-95EC-C78C34A9361CQ33558421-31AFC778-917A-4D6D-9CB3-9763E8089EAEQ33571558-06632475-C8AB-4573-8423-4E283BDA1515Q33701317-4AD8A81E-FFF7-47AC-BAF6-D9AC956A666BQ33785157-4F054408-56F3-403D-BFAA-165057D96AAAQ33804684-75B88742-A5A0-41C5-BCF7-8F0D175F10CCQ33891703-AA187AF1-BC12-42C8-9C62-BDD772D84EA1Q34313633-0FE9B735-FD9C-4A3D-9D18-B96088266B4CQ34358231-A92224B0-4559-4D18-9367-BA9F4327B568Q34425055-9377BB65-377C-4D83-825F-3451D7E5C201Q34496850-F1049E28-0C7D-4F3A-B5E2-948836A39946Q34533154-AFABFED3-FDA3-424D-9474-1DAE7748574CQ34553052-614B2FCE-98B9-43F2-AAFF-065E88E7A0AAQ34641965-DE8E5333-32ED-459C-9076-6A9B5084035FQ34762475-BC2CB5B1-C9B3-4254-9D37-C5CE2296859BQ34842230-CD80AECD-0D69-4AE2-B060-D6BBD2C379B0Q34873090-95D19BD1-2158-47AF-86F2-F35443889208Q35004314-D3D3FAF1-B545-4EA9-8082-7F8B4826C073Q35013431-60B73B21-8EE0-4423-BE5D-34EFED3DE811Q35165905-4976E350-6826-4C61-B0C4-59B222823A4BQ35184731-B94B258A-25F7-441A-80F5-FE7CF4E64CE5Q35434962-0559DCEC-5C35-48B2-A05A-74708D98177AQ35669997-0C0061A5-2C36-4F89-9B8D-4E8F8E1A6642Q35691425-0053F6FE-CA28-4E1A-A3CC-E598FDC51FB4Q35893638-0F7DE45F-37EE-4D66-8BA1-5B5119889D36Q35896615-F5281754-17DC-46DF-9937-031B04B18E6FQ36236701-22AEA734-3B11-4E2A-8EC5-F50B6DE74499Q36251379-7A38DD46-60E1-49A1-8B10-BA1D53AC8172Q36535440-C46F776F-6F10-40A4-A18D-F5C68CDF764A
P2860
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuropathy among the diabetes ...... years after trial completion.
@en
Neuropathy among the diabetes ...... years after trial completion.
@nl
type
label
Neuropathy among the diabetes ...... years after trial completion.
@en
Neuropathy among the diabetes ...... years after trial completion.
@nl
prefLabel
Neuropathy among the diabetes ...... years after trial completion.
@en
Neuropathy among the diabetes ...... years after trial completion.
@nl
P2093
P2860
P1433
P1476
Neuropathy among the diabetes ...... years after trial completion.
@en
P2093
Barbara Waberski
Catherine L Martin
DCCT/EDIC Research Group
Douglas A Greene
Eva L Feldman
James Albers
Martin J Stevens
Patricia Cleary
William H Herman
P2860
P304
P356
10.2337/DIACARE.29.02.06.DC05-1549
P407
P577
2006-02-01T00:00:00Z